SOPHiA GENETICS Unveils Strategy to Drive Innovations in Healthcare at Inaugural Investor Day Event

Highlights include: a memorandum of understanding with Memorial Sloan Kettering Cancer Center and an unprecedented new partnership with Boundless Bio, a next-generation precision oncology company

SOPHiA GENETICS’ next-generation CarePath solution, powered by current real-world observational data, previewed to attendees

BOSTON and GENEVA, September 21, 2022 /PRNewswire/ — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare software company, held its first-ever Investor Day on Tuesday, September 20, 2022in New York City.

The event, hosted by CEO and Co-Founder Dr. Jurgi Camblong and members of the leadership team, provided a roadmap of the company’s long-term vision and highlighted new opportunities business and new partnerships. One of the takeaways from the event was SOPHiA GENETICS’ acceleration into the biopharmaceutical space, which opens the door to new market growth opportunities. The audience also heard how the company’s strategic business model allows it to continue to provide solid depth in the clinical space.

“A key theme throughout the day was how we innovate; how SOPHiA GENETICS, since its inception, has identified opportunities in the healthcare industry for innovation and accelerating data sharing to advance medicine, research and patient care,” said Jurgi Camblong , CEO and Co-founder, GENETIC SOPHIA. “Our vision is made possible by the strong foundation our company has been built on, as well as the strategic relationships we have forged to further our mission of democratizing data-driven medicine.”

New collaboration with one of the top ranked cancer centers in United States

SOPHiA GENETICS recently announced a memorandum of understanding to enter into collaboration with Memorial Sloan Kettering Cancer Center (“MSK”). Once signed, the collaboration agreements will combine the power of SOPHiA GENETICS’ extensive global network and deep expertise in predictive algorithms with MSK’s clinical expertise in cancer genomics. The collaboration agreements will also allow SOPHiA GENETICS’ global network of healthcare providers to access MSK’s proprietary tumor sequencing assays such as MSK IMPACT®, for tumor analysis. Additionally, the collaboration agreements will combine MSK’s rich precision oncology data with the SOPHiA CarePath™ module to enable the acceleration of actionable insights from the data to improve patient outcomes.

“Our vision is to expand access to world-class data, including our current network, which contributes to the collective intelligence of the SOPHiA GENETICS platform,” said Philippe Menu, MD-Ph.D., medical director, GENETIC SOPHIA.

Enabling biotechnology to develop new cancer therapies targeting oncogene amplification

SOPHiA GENETICS announces a partnership with Unlimited Bioa next-generation precision oncology company developing innovative therapies directed against extrachromosomal DNA (ecDNA) in oncogene-amplified cancers.

It has been well established that patients with oncogenic amplification generally do not benefit from standard cancer treatments and, unlike other forms of oncogenic gene alterations, oncogenic amplification frequently occurs on ecDNA. ecDNAs are circular units of nuclear DNA that are distinct from normal chromosomes and are the primary site of high copy number amplification in cancer. Boundless Bio is developing the first ecDNA-directed therapies (ecDTx) as well as a precision diagnostic method called ECHO (ecDNA Harboring Oncogenes) to detect ecDNA from a patient’s routine tumor sequencing data.

The partnership between Boundless Bio and SOPHiA GENETICS will further develop ECHO for use in ecDTx clinical trials.

SOPHiA GENETICS unique ability to harmonize data derived from various genomic instruments and deploy them as a robust and standardized solution enables a new model for clinical trial testing. This decentralized global genomics solution, combined with Boundless Bio’s ecDTx drug development capabilities, aims to unlock value by breaking down the barriers inherent in the traditional central lab approach; optimize patient selection and clinical trial design; and enable a global collective network of leading hospitals and academic centers to effectively deliver new treatment options to patients with oncogene-amplified cancers.

“We are delighted to partner with SOPHiA GENETICS for the development of Boundless Bio’s ecDNA detection algorithm, ECHO, into a clinical trial device,” said Pierre Kerin, Ph.D., Vice President of Precision Medicine at Boundless Bio. “The ability to identify patients with ecDNA-induced tumors is critical to our mission to address this area of ​​unmet medical need. SOPHiA GENETICS’ unique expertise in developing IVD NGS software algorithms based on the cloud makes it an ideal partner to develop ECHO into an experimental device.”

Multimodal DEEP-Lung-IV Clinical Study Powers New SOPHiA Carepath Platform

At the end of 2021, SOPHiA GENETICS launched a DEEP-Lung-IV Multimodal Clinical Study with the aim of aggregating real-world multimodal (genomic, clinical, biological and radiomics) data for patients with metastatic non-small cell lung cancer. The study has attracted interest from leading centers globally, with a strong trend in patient recruitment; to date, nearly 900 patients at 23 sites have been recruited for the study. As patients were followed through the patient journey, datasets were collected and analyzed by SOPHiA GENETICS’ machine learning algorithm to predict how patients will respond to immunotherapy and why.

This robust and growing patient data will inform SOPHiA GENETICS’ artificial intelligence and machine learning that will power the upcoming SOPHiA CarePath™ module, a new product to be launched on the SOPHiA DDM™ platform and aims to be the vehicle that healthcare practitioners can use to take advantage of real-time, real-time insights gained through this study. The SOPHiA CarePath™ module will provide the following benefits:

  • View single patient data holistically (genomics, clinical, biological, and radiomics)
  • Allow providers to group patients in the context of similar patients from other facilities

Along with these announcements, a full recording of the event is available on the Investor Relations company website page.


SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life science research. He is the creator of the SOPHiA DDM™ platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal datasets and different diagnostic modalities. The SOPHiA DDM™ platform and associated solutions, products and services are currently used by an extensive network of hospitals, laboratories and biopharmaceutical institutions around the world. For more information, visit SOPHiAGENETICS.COMor log on to Twitter, LinkedIn, Facebookan/a instagram. Where Others See Data, We See Answers

SOPHiA GENETICS products are for research use only and should not be used in diagnostic procedures unless otherwise specified. The information in this press release relates to products that may or may not be available in different countries and, where applicable, may or may not have received marketing approval or clearance from a government regulatory body for different indications for use. please contact [email protected] to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS forward-looking statements:

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical fact contained in this press release, including statements regarding our future operating results and financial condition, business strategy, products and technology, and plans and objectives for direction for future operations, are forward-looking statements. . Forward-looking statements are based on the beliefs and assumptions of our management and on information currently available to our management. These statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied by the forward-looking statements due to a variety of factors, including those described in our filings with the Securities and Exchange. United States Commission. No assurance can be given that these future results will be achieved. These forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update any forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions or circumstances on which such statements are based, unless required to do so. by the rights. No representation or warranty (express or implied) is made as to the accuracy of these forward-looking statements.